Related references
Note: Only part of the references are listed.The hepatotoxicity of antifungal medications in bone marrow transplant recipients
MA Fischer et al.
CLINICAL INFECTIOUS DISEASES (2005)
Effect of age and postoperative time on cytochrome P450 enzyme activity following liver transplantation
SS Liu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
A single solution for multiple organ procurement and preservation
G Karam et al.
TRANSPLANT INTERNATIONAL (2005)
Cytochrome P450 3A polymorphisms and immunosuppressive drugs
E Thervet et al.
PHARMACOGENOMICS (2005)
Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 activities in human liver microsomes
T Niwa et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2005)
57 varieties: the human cytochromes P450
DFV Lewis
PHARMACOGENOMICS (2004)
Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population
JF Solus et al.
PHARMACOGENOMICS (2004)
Some aspects of interindividual variations in the metabolism of xenobiotics
V Tamási et al.
INFLAMMATION RESEARCH (2003)
Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively
X Wen et al.
DRUG METABOLISM AND DISPOSITION (2002)
Late hepatic allograft dysfunction
RH Wiesner et al.
LIVER TRANSPLANTATION (2001)
Pharmaco genetics: an opportunity for a safer and more efficient pharmacotherapy
M Ingelman-Sundberg
JOURNAL OF INTERNAL MEDICINE (2001)
Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin
M Tanaka et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
Effects of the antifungal agents on oxidative drug metabolism - Clinical relevance
K Venkatakrishnan et al.
CLINICAL PHARMACOKINETICS (2000)
Share Paper
